PharmaEssentia Corporation aims to deliver efficacious, safe and cost-effective therapeutic products for the treatment of human diseases while aiming to bring long lasting value to our stakeholders. At PharmaEssentia, our mission is a never-ceasing commitment to the improvement of health and quality of life. PharmaEssentia was founded in 2003 by a group of Taiwanese-American executives and high-ranking scientists from leading biotechnology and pharmaceutical companies in the US, with a goal to develop treatments for myeloproliferative neoplasms, hepatitis and other diseases.
Our flagship product is a new generation ropeginterferon alfa-2b (P1101), developed using our novel PEGylation technology platform. This has resulted in a much purer pegylated interferon (>90% 1 predominant isomer vs. PegIntron’s 14 isomers and Pegasys’ 8 isomers). The main problem with the current pegylated interferons (PegIntron and Pegasys) are patient tolerability, as these drugs induce severe flu-like symptoms and neuropsychiatric side effects. As a result of our purer profile, we have seen data that indicates improved tolerability, compliance and thus long-term treatment outcomes. We are able to administer our product once every two weeks (vs. every week for other pegylated interferons) for enhanced tolerability. We plan to explore ropeginterferon alfa-2b in a variety of indications, including myeloproliferative neoplasms (MPNs) and hepatitis B and C.
|2017||PharmaEssentia approves EMA’s PAI (Pre-Approval Inspection) for PV.|
|2018||The data of P1101 (Ropeginterferon alfa-2b) for PV in Phase III shows superiority in Durable Response for HU patients.|
|2018||AOP, the partner of PharmaEssentia in EU, has submitted the D120 LoQ to EMA and is expected to obtain the approval at the end of 2018.|
|2019||The Marketing Authorization For Ropeginterferon alfa-2b (Besremi) is granted by EMA.|